My watch list  
More about Meda
  • News

    BioPhausia focuses and sells OTC products to Meda for SEK 190 million

    BioPhausia signed an agreement to sell its portfolio of OTC products to Meda for a total of SEK 190 million, plus the value of the inventory. The Company has also completed the previously communicated strategic review of its generics portfolio, allowing further concentration on prescription ... more

    Meda acquires Alaven, a US specialty pharma company

    Meda has signed an agreement to acquire the US specialty pharmaceutical company Alaven. The acquisition will significantly enhance Meda’s marketing capabilities in the US and expand the therapeutic focus to include both gastroenterology and women’s health; areas that Meda already operates i ... more

    Meda: Onsolis receives FDA approval

    The U.S. Food and Drug Administration (FDA) has approved Onsolis (fentanyl buccal soluble film). This new and patented product is indicated for the management of breakthrough pain in cancer patients who are already receiving and who are tolerant to opioid therapy for their underlying persis ... more

  • Companies

    Meda Pharma GmbH


    Meda Pharmaceuticals Inc.

    MEDA PHARMACEUTICALS INC. is the U.S. subsidiary of Meda AB. Meda Pharmaceuticals specializes in respiratory, allergy, central nervous system, and cough-cold products. MEDA AB is an international specialty pharma company that concentrates on marketing and market-adapted product development ... more

    Meda Pharma S.A.U.

    Meda is an international specialty pharma company that covers all of Europe and the US via its subsidiaries in 26 countries and more than 1500 employees in marketing and sales. In other world markets, agents and other pharma companies market and sell Meda's pharmaceuticals. more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE